SynthesisBMC surgery2025
Aspirin as a viable alternative to oral anticoagulants for VTE prevention after hip arthroplasty: a meta-analysis of randomized clinical trials.
Synthesis in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHip arthroplasty is effective for advanced osteoarthritis but poses a high venous thromboembolism (VTE) risk without prophylaxis; this study aimed to evaluate whether aspirin is as effective and safe as oral anticoagulants (OACs) for VTE prevention in this setting.
methodsPubMed, EMBASE, Web of Science, and the Cochrane Library were searched for studies up to June 01, 2024. The primary outcome was VTE incidence, including deep vein thrombosis (DVT) and pulmonary embolism (PE); secondary outcomes included bleeding and wound complications.
resultsSix RCTs involving patients undergoing hip arthroplasty were included. The pooled results demonstrated that aspirin had a comparable effect to OACs in preventing VTE (RR 0.90, 95% CI 0.63–1.29), with no significant differences observed in the incidence of DVT or PE. Additionally, no notable differences between the two groups in terms of bleeding risk or wound-related complications, although these safety outcomes were reported in fewer studies. Importantly, subgroup analyses across all pre-specified factors consistently supported the main findings, and no heterogeneity was observed in any outcome (I2 = 0% for all analyses).
conclusionsBased on existing RCT evidence, aspirin is as effective and safe as OACs for preventing VTE, DVT, and PE after hip arthroplasty, without increasing adverse events. The reliability of our conclusion is strengthened by the absence of heterogeneity in all our results, including those from subgroup analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.